The sale provides immediate cash but removes a pipeline asset; Theriva now focuses on its oncolytic adenovirus platform (VCN-01). Monitor Biossil's progress in advancing the Phase 1b/2a trial for SYN-004 in aGVHD and any regulatory milestones that would trigger payments to Theriva.
Drugs in focus
TOVX drug pipeline →VCN-01
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2b completed; Phase 2a (VIRAGE2) authorized/enrolling; Phase 3 design aligned with FDA and EMA
- Time to market
- Likely 4-6 years if Phase 3 is successful, assuming the company secures funding/partnership to initiate a pivotal trial
- Next catalyst
- None dated
What to watchVCN-01 is the only meaningful asset at a ~$10M market-cap company. The positive VIRAGE Phase 2b data and FDA/EMA alignment on Phase 3 design are real positives, but the company has only ~$14M cash (runway into Q1 2027) and needs a partnership or dilutive financing to fund the pivotal trial. Watch for partnership/licensing announcements and VIRAGE2 interim data as the next catalysts, the stock is highly binary and prone to large swings.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $0.1820entry
- T+1 · 13d ago +4.40%α +2.74% · $0.1900
- T+5 · 7d ago −15.27%α −14.69% · $0.1542
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theriva Biologics sold its SYN-004 (ribaxamase), SYN-007, and SYN-006 antibiotic-degrading enzyme portfolio to Biossil Labs for a $350,000 upfront payment, with potential regulatory milestones up to $3 million, sales milestones up to $88 million, low single-digit royalties capped at $250 million, and a low-double-digit percentage of license consideration. The transaction closed concurrently with the agreement on October 30, 2026, and Theriva also amended its existing agreement with PREV ABR LLC, paying $140,000 at closing and agreeing to share a portion of future proceeds from the Biossil deal, subject to a $13 million cap. The sale allows Theriva to focus on its oncolytic adenovirus platform (VCN-01) while retaining upside through contingent payments.
Key Financial Metrics
Key Facts
- Theriva sold its SYN-004 (ribaxamase), SYN-007, and SYN-006 assets to Biossil Labs for a $350,000 upfront payment.
- Theriva is eligible for up to $3 million in regulatory milestones, up to $88 million in sales milestones, low single-digit royalties capped at $250 million, and a low-double-digit percentage of license consideration.
- The closing occurred concurrently with the execution of the Asset Purchase and Sale Agreement on October 30, 2026.
- Theriva amended its 2012 agreement with PREV ABR LLC, paying $140,000 at closing and agreeing to share 50% of regulatory/sales milestones, 33.33% of royalties, and 50% of other consideration from the Biossil deal, subject to a $13 million aggregate cap.
- Theriva retains no ownership or control over the sold assets; Biossil has sole control over development and commercialization.
- Theriva's market cap is approximately $9 million, making the $350,000 upfront payment material (about 3.9% of market cap).
Financial Impact
Upfront cash consideration of $350,000 (net of $140,000 paid to PREV = $210,000 net to Theriva), with contingent upside up to $341 million in milestones and royalties, though highly uncertain. The $350,000 represents ~3.9% of Theriva's $9M market cap.
Risk Factors
- No assurance that any milestones will be achieved or that any product will be approved or commercialized.
- Theriva's future payments are contingent on Biossil's development success and commercial performance, over which Theriva has no control.
- The PREV amendment requires Theriva to share a significant portion (33-50%) of future proceeds from the Biossil deal, reducing net upside.
- Theriva's remaining pipeline (VCN-01) is early-stage and carries its own development and regulatory risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-121318 |
| Document: tm2628598d1_8k.htm | 0001104659-26-121318 |
| Document: tm2628598d1_ex10-2.htm | 0001104659-26-121318 |
| Document: tm2628598d1_ex99-1.htm | 0001104659-26-121318 |
| Document: 0001104659-26-121318-index-headers.html | 0001104659-26-121318 |
| Document: 0001104659-26-121318-index.html | 0001104659-26-121318 |
| Document: 0001104659-26-121318.txt | 0001104659-26-121318 |
Track record
11 reports on TOVX
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 Viewing Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
- Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
- Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
- Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
- Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
- Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers